Homologous, and to a significantly lesser extent, autologous blood transfusion is associated with definable and potentially serious risk. The increasing professional and public awareness has led to a critical evaluation of transfusion practices and a change in transfusion philosophy towards optimising transfusion therapy for individual patients. This involves the provision of the safest blood and the minimisation of homologous blood exposure. Autologous blood transfusion is not without risk as misidentification of patient or unit, bacterial contamination and volume overload can occur; consequently, the indications for the transfusion of autologous blood, as per homologous units, must be appropriate to the clinical circumstances. Appropriate transfusion criteria are being developed and lower haemoglobin levels are becoming accepted.
In the 1990s the medical and general communities have become increasingly aware of infective transfusion risks. This has led to a critical evaluation of transfusion practices by both profession and media and is being increasingly directed towards the minimisation of transfusion risk. The spectrum of transfusion practice is changing towards the provision of the safest blood, autologous in elective surgery for example, and to the minimisation of homologous blood exposure. [1] [2] [3] Appropriate transfusion criteria are being developed and adopted and lower haemoglobin levels are becoming accepted. 4 -7 Hospital quality assurance and transfusion committees, driven by the medico-Iegal "duty to warn" and "to advise" are looking at the appropriate use of blood in their own case mix and demographic profiles.
Transfusion morbidity and mortality however, extends beyond the well publicised and encompasses other, more usually immune-mediated transfusion reactions. Knowledge of these must be reviewed periodically to enable an informed risk-benefit evaluation to be made prior to the transfusion decision. Similarly, the transfusion decision must be complemented by adequate clinical assessment, preoperative haemostatic assessment and attention to surgical technique. Considerations of laboratory parameters, clinical co-morbidities, potential benefits of pharmacological interventions with DDAVP 8 -9 and erythropoietin 9 -JO are also important in minimising risk to the patient.
How safe is blood? What is the morbidity and mortality and what preventative and therapeutic options are available? Transfusion reactions can be classified by their time of occurrence, immediate or delayed, and by their immune and non-immune basis ( Figure 1 ). The bi-directional nature of immune transfusion reactions is an important consideration and can result from an antibody-or cell-mediated incompatibility. These bi-directional antibody-mediated immune reactions can result from specific antibody, present in recipient, donor, or donor against donor plasma, which is directed against red cells, HLA, granulocyte-specific, platelet-specific and against plasma protein antigens II-IS and which are clinically manifested by haemolysis and febrile, respiratory and allergic transfusion reactions. Some may result in disseminated intravascular coagulation (DIC), complement activation and death, e.g. ABO incompatible blood transfusion; others may simply be an inconvenient transfusion reaction, requiring little in the way of symptomatic therapy. Cell-mediated immune transfusion reactions may be manifested as transfusionrelated graft-versus-host disease 11.12 or as an immune down-regulation in the recipient with consequent increase in septic complications [16] [17] [18] Bacterial contamination of blood may result in septic shock, DIC and death,20 which is clinically indistinguishable from an acute haemolytic transfusion reaction. Transfusion-related AIDS, hepatitis and other infections have increasingly assumed a greater significance in transfusion fatalities. 21 Other non-immune transfusion fatalities have also been reported to occur from physical injury to red cells in association with thermal, chemical, or osmotic insults, II".CC and from iron and circulatory overload. Similarly, drugs coadministered with red cell transfusions may result in haemolysis of patient or donor blood, e.g. glucose-6phosphate dehydrogenase deficiency.2J
At the Repatriation General Hospital, Concord, an ongoing transfusion surveillance program has been in operation since 1988 and all patients receiving blood and blood products are assessed for the presence of adverse reactions within the first 24-72 hours. To date, transfusions of over 30,000 units of red cells, platelets and FFP have been followed; 3.5070 of the patients and 1 in 30 transfusion episodes results in some morbidity. For every febrile transfusion reaction another patient will manifest either an allergic, respiratory, haemolytic or infective complication, morbidities not evident in patients receiving autologous blood. 7 On average at RGH Concord, two cases of clinical post transfusion hepatitis are seen per year and there is no true indication of the prevalence of anicteric cases. In the year prior to commencement of this surveillance program, two patients received units contaminated with cryophilic organisms, Streptococcus lactus and Enterobacter agglomerans (patient I) and Yersinia enterocolitica (patient 2). Both units of blood were more than 25 days old when transfused and both recipients became acutely ill. One died within 12 hours of transfusion and the second had a protracted hospital course, multiple complications and subsequently died of his underlying secondary carcinoma. In patient 2, the Yersinia infection contributed significantly to morbidity if not mortality. No unit subsequently transfused in this series has been associated with bacterial contamination.
The advantages of autologous blood include the prevention of disease transmission, alloimmunisation and transfusion reactions. 13 Whole blood viscosity is lowered, homologous blood supply is conserved and erythropoiesis is stimulated. Accelerated erythropoiesis, the "hidden" benefit of autologous predeposit programs, has been well demonstrated in a baboon model. " Predeposit and control groups at laparotomy underwent exchange transfusion to a haematocrit of 15070 and recovery time to haematocrit 20070, 25070 and 30070 was monitored. Compared with controls, the predeposit autologous group demonstrated a higher reticulocytosis, shorter recovery time and an enhanced erythropoietic response to anaemia in the postoperative period. "
Autologous blood transfusion is not without risk. Misidentification of the patient or unit, bacterial contamination and volume overload can occur, and haemolysis due to inadequate deglycerolisation of thawed frozen units has recently been reported. '" Consequently, the indications for the transfusion of autologous blood must also be appropriate to the clinical circumstances.
Transfusion-related mortality is infrequently reported. Sazama reviewed 355 such cases occurring between 1976-1985; 16 deaths were unrelated to transfusion and 12 reflected donation deaths which were then excluded from further analysis. 22 Acute haemolytic deaths accounted for 164 of these transfusion deaths; 96070 were immune-medicated and 80070 were due to ABO errors, with group 0 recipients at greatest risk of receiving incompatible blood. Several deaths also resulted from the passive transfusion of anti-A or anti-B in whole blood or plasma to group B or group A individuals respectively. Death resulting from ABO incompatibility has occurred with as little as 30 ml to over three units of blood, the most frequent lethal dose being one unit. 22 Whilst the correlation between volume of incompatible blood transfused and the severity of the reaction is not a strong one, in general, larger volumes are associated with more profound consequences. Similarly, there have been rare cases of immediate haemolytic transfusion deaths resulting from the passive transfer of anti-Kell, Rhesus, Duffy and Kidd antibodies, some of which have been implicated in inter-donor transfusion reactions. 11 ." Anaphylactic shock and graft-versus-host disease were ·tf/(f{')ll/c)ia and Iflh'l/"il'e Care, ~()/. 21, .\'0. /, i'ehruary, 1993
documented as cause of death in only a few cases. 22 The deaths attributed to hepatitis (42 non-A non-B hepatitis, 26 hepatitis B) and three to AIDS were felt to be inconsistent with other predicted and reported data from CDC Atlanta and were also not reviewed further. 22 Pulmonary oedema or respiratory insufficiency accounted for 15<JJo of deaths, and 26 patients or lO<JJo of deaths reflected bacterial contamination of whole blood, platelets or cryoprecipitate due to donor bacteraemia, faulty collection technique, and errors in fractionation or thawing. 22 The next decade will see different transfusion-related mortality data with infective deaths predominating. In the USA for example, the transfusion of blood and components has been shown to be the only identifiable risk in at least 2,213 cases of AIDS. 25 The classical acute haemolytic transfusion reaction may manifest all the symptoms and signs associated with antigen-antibody complex formation and complement activation to the formation of the membrane attack complex. Complement comprises a series of nine protein groups, most of which have a dimer structure and are located in the beta region of human sera. Complement activation represents a sequential proteolytic cascade through components 3 to 10 which can be started via two pathways: classical and alternative. This results in the production of complement peptides, split off from their parent molecules, which are responsible for mast cell degranulation with resultant histamine release, neutrophil chemotaxis and immune adherence at sites of complement activation. Complement activation may be triggered through the classical pathway via IgG and IgM which triggers the binding of Clq, C2 and C4. The antibodies initially bind to either Fc receptors or other molecules on cell surfaces, e.g. red blood cell antigens, by their Fab binding sites. The specific aggregation of all these proteins leads to C3 deposition and cleavage at the cell surface, with subsequent recruitment, attachment and cleavage of C5, C6, C7, C8 and C9, to form a doughnut-shaped attack complex which causes a physical hole to be punched in the cell membrane, leading to lysis. The lytic activity, visualised by the formation of a "doughnut"type channel 26 or a "leaky-patch", 27 results in red cell haemolysis and activation of the clotting cascade.
Coexisting with complement activation, there is activation of factor XII and release of bradykinin with resultant hypotension, pain and bronchospasm. The generation of the vasoactive amines, C3a and C5a, also mediates the initial hypotension and shock of an acute haemolytic transfusion reaction. The secondary release of catecholamines leads to renal vasoconstriction and acute renal failure which may be compounded further by fibrin thrombi deposition secondary to DIe.
Anaesthesia and Intensive Care, Vol. 21. No. I. Fehruary. 1993 DIC results from the intravascular coagulation of the haemostatic system in response to injury. The central components of the DIC syndrome are the generation of thrombin with consumption of coagulation factors and a secondary fibrinolysis. 28 It is likely that tumour necrosis factor and other cytokines such as interleukin 1 and platelet activating factor may have a more general pathogenic role in acute DIe. 29 In the majority of patients with acute DIC, haemostatic failure dominates the clinical picture. Disseminated microthrombi involving the kidneys, brain, skin, adrenal, pituitary and lungs have all been documented. 30 Fibrin deposition in the microcirculation may result in a microangiopathic haemolytic anaemia. 30 The laboratory features of DIC include thrombocytopenia; coagulation test abnormalities suggestive of consumption with hypofibrinogenaemia and prolonged clotting times; evidence of increased fibrinolysis with elevated fibrin degradation products (FOPs), shortened clot lysis times and positive paracoagulation tests; and much less commonly, microangiopathic changes in RBC morphology. No single test is diagnostic and not all tests may be positive in a given patient.
A severe acute haemolytic transfusion reaction may present dramatically with acute pain along the vein, chest and back, hypotension, flushing, fever, dyspnoea, agitation, vomiting, diarrhoea and haemoglobinuria. 31 More often however, it may present with subtle symptoms and signs and as such should be considered in the differential diagnosis of a febrile transfusion reaction. 32 In the 47 cases of an immune haemolytic transfusion reaction at the Mayo Clinic, fever with or without chills was the commonest initial manifestation and, with the exception of one patient with haemoglobinaemia, all the other symptoms and signs were not particularly specific. 32 Similarly, in an anaesthetised or intensive care patient, the presentation is often more subtle with hypotension, increased bleeding and, only when the serum haptoglobin is fully saturated, with haemoglobinuria. Acute renal failure has been reported to occur in 5-13<JJo cases 31 -33 and DIC, with an approximate lO<JJo mortality, occurs in from 5-8<JJo cases. [31] [32] [33] Two sequential series from the Mayo Clinic estimated the incidence of acute haemolytic transfusion to be 1 in 12,000 32 and 1 in 21,000. 34 More recent studies estimate this incidence to be closer to 0.5-1.0 in 100,000 units transfused. 22 Transfusion to the wrong patient was by far the greatest contributor to immunehaemolytic transfusion deaths and accounted for 39-49<JJo of deaths. 22 ,15 Errors also occurred in the collection and ordering of blood, and in the Blood Bank."'" Within a 24-month period, five ward patients in a large teaching hospital mistakenly received blood crossmatched for different patients due to identification errors. Most of these errors occurred at the transfusion administration step but no serious sequelae occurred. 36 Similarly, misidentification of the patient occurred in the operating room on 59070 of occasions J5 falling to 32.5070 in a later study. 22 Misidentification also occurred in the wards, intensive care, and accident and emergency units, and compound clerical errors, involving two persons, were reported on 1 in 7 (14.3070) occasions."''' Wherever errors could be made they were, and Sazama attributed the majority of these failures in patient or sample identification to "management" errors, i.e. a lack of standard operating protocols and lack of appropriate educational programs. 22 Therapy in an acute haemolytic transfusion reaction is aimed at reversing the potential lethal consequences related to arterial hypotension and shock, renal failure and DIe. The transfusion should be ceased, a clerical check performed to check the identification of the unit and patient, and renal perfusion should be maintained with normal saline and frusemide. Low-dose dopamine may be required and DlC should be managed with supportive therapy such as FFP and platelets. The use of heparin remains controversial. Diagnosis must be made concurrently with active treatment and investigations are aimed at documenting intravascular haemolysis (haemoglobinaemia, haemoglobinuria, urinary haemosiderin, serum haptoglobin, Schumms, bilirubin and serum lactate dehydrogenase). In addition a blood film examination should be performed looking for spherocytes and shistocytes, and other investigations should be directed to documenting an alloimmune cause (direct Coombs test, group checking the unit(s) transfused, repeating the group and screen on both pre-and post-transfusion samples) and to assess the presence of co-existing DIC (prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and fibrinogen degradation products).
Delayed haemolytic transfusion reactions (DHTR), involving antibodies to the Kidd, Kell, Duffy, Rhesus and other antigen systems, either alone or in combination, resulted in 10070 of reported deaths and predominantly occurred 6-16 days post transfusion. 22 The prevalence of DHTR varies from 1 in 11,650 37 to 1 in 1,500 units transfused. 3. The antibodies most often implicated are those directed against the Rh (34070), Kidd (30070), Duffy (14070), Kell (13070) and MNSs (4070) antigen systems. Each unit transfused and every pregnancy is associated with a 1070 isosensitisation risk. ".) 9 A more recent study shows that delayed haemolytic transfusion reactions can be viewed as a subgroup of delayed serologic transfusion reactions (DSTR), the latter defined by the development of a positive direct Coombs test post-transfusion and the presence of an alloantibody in serum and/or eluate. Over a 20-month period, 34 DSTR were identified with an incidence of 1 in 1,605 units transfused (0.06070), most evident in multi-transfused patients; there were only six delayed haemolytic transfusion reactions, of which only two were clinically recognised. The incidence of DHTR in this series was therefore 119,094 units (0.0l (70).40 The serologic observation has increased but the clinical features of anaemia, jaundice and often fever, evident most commonly 7-14 days post transfusion, is probably unchanged. Haemoglobinuria may occur and rarely acute renal failure and DIC have been reported. 32 Hospital transfusion practice is becoming increasingly focused on the minimisation of risk to the patient. Homologous, and to a significantly lesser extent, autologous blood transfusion is associated with definable and serious risks. Where the magnitude of the risk is great or where the prevalence of a complication is high then these factors should be incorporated in the evaluation of the risk-benefit equation and in the resultant clinical decision to administer blood. This holistic view acknowledges the risks of homologous blood transfusion and the complementary approaches to optimise both patient and transfusion factors.
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